DexCom (DXCM) EVP Michael Jon Brown Sells $145K of Stock

By TradeTexts Research Desk Oct 19, 2026, 7:02 PM EDT

Key Points

DexCom, Inc. EVP Michael Jon Brown sold 1,700 shares on October 15, 2026, at an average price of $85.48 per share.
After the trade, Michael Jon Brown holds 98,185 $DXCM shares, down 1.70% from before the trade.
The medical device maker posts $4.97 billion in trailing twelve-month revenue with a 20.1% net profit margin ahead of its October 29, 2026 earnings report.
Wall Street firms maintain an overall strong buy consensus on the stock with a mean price target of $96.46.

Since the trade, $DXCM is down 1.9% to date (from the $87.71 close on Oct 15, 2026).

Get DexCom text alerts

We text you when insiders, Congress, analysts or big funds move on $DXCM.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated DexCom, Inc. alert may contain errors. Disclosures

DexCom, Inc. EVP Chief Legal Compliance Off Michael Jon Brown sold 1,700 shares of the medical device maker on October 15, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the transaction was executed at a price of $85.48 per share for a total value of $145,316. DexCom closed at $87.71 on the day of the trade.

DXCM DexCom, Inc.

$86.04 +29.31% year to date

Daily close · Oct 16, 2026

Inside Michael Jon Brown's DXCM Trade

The planned sale was carried out under a pre-arranged trading plan. Following the transaction, Brown directly holds 98,185 shares of the company, cutting his stake about 1.7%.

Other Institutional Activity in DexCom

Large asset managers adjusted their holdings in the medical device maker earlier in the year. Baillie Gifford & Co grew its holdings by -798737 shares, ending with 14,801,590 shares worth about $1,272,640,757 after a 5.1% decrease. Alliancebernstein L.P. reduced its stake by 1,230,341 shares, ending with 11,693,409 shares valued at $1,005,399,345 following a 9.5% decrease.

DexCom, Inc. Stock Down 0.1%

The stock recently traded around $85.98 as of October 19, 2026, sitting about 2.0% below its event-day close. The shares trade below its 50-day moving average of $87.55 and above its 200-day moving average of $73.97.

Recent Earnings

DexCom reports trailing twelve month revenue of $4,969,200,128 with a net profit margin of 20.1% and earnings of $2.52 per share on a trailing basis. The company has a return on equity of 38.5%. The next earnings report is scheduled for October 29, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

D 42/100

Reported Apr 30, 2026

Forward outlook
4 target cuts vs 0 raises.
EPS & revenue
EPS beat estimates by 17.0%. Revenue missed estimates by 0.5%.
Profit surprise
EBITDA beat by 5 percent. Operating income beat by 21 percent.
Pre-earnings setup
Bar was high, analysts already very bullish.
Analyst signal
4 target cuts.
Earnings quality
Gross margin up 6.1 points. Operating margin up 8.5 points. Positive free cash flow.

Earnings Call Summary

DexCom delivered first-quarter revenue of $1.19 billion, up fifteen percent year over year, with strong international growth of twenty-six percent. The company achieved record global new patient starts and grew U.S. market share significantly in the type 2 non-insulin segment, driven by the G7 15-day launch and better product algorithms. Management highlighted upcoming announcements including randomized control trial results at the ADA conference and new basal insulin features designed to simplify diabetes treatment.

Guidance DexCom reaffirmed full-year revenue guidance of about $5.18 billion, representing growth of eleven to thirteen percent. The company raised full-year operating profit and EBITDA margin guidance, citing strong cost control and manufacturing improvements. Management expects continued momentum from the G7 15-day product launch and potential coverage expansion for type 2 non-insulin patients later in the year.

Clearly negative report. The company missed important expectations and likely triggers downward revisions.

Insider Buying and Selling at DexCom, Inc.

Chief Financial Officer Jereme M Sylvain sold 3,638 shares on September 10, 2026, at $83.27 per share for a total of $302,936. Officer Michael Jon Brown sold 1,700 shares on September 15, 2026, at $84.04 per share for $142,868. Director Nicholas Augustinos sold 8,089 shares on September 15, 2026, for $679,769. Officer Sadie Stern sold 2,565 shares on September 28, 2026, at $86.15 per share for $220,975.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the upcoming earnings release. On September 18, 2026, Truist Securities maintains the stock with a Buy rating and a $102.0 price target. On September 18, 2026, TD Cowen reiterates a Buy rating with a $95.0 target. On October 1, 2026, RBC Capital maintains an Outperform rating with a $105.0 target. On October 7, 2026, Barclays initiates an Overweight rating with a $115.0 target. On October 12, 2026, BTIG maintains a Buy rating, raising the target to $96.0. The stock carries a consensus strong buy rating with an average price target of $96.46.

About DexCom

DexCom, Inc. designs and develops continuous glucose monitoring systems to help people manage diabetes and check metabolic health. The San Diego-based medical device maker operates in the healthcare sector, serving patients in the United States and internationally.

Bottom Line

Insiders routinely buy and sell shares for personal financial planning purposes. Investors should review upcoming financial results on October 29, 2026, to monitor the company's growth trajectory.